Kojin
Kojin Therapeutics is the first biopharmaceutical company using ferroptosis biology to develop novel therapeutics.
Challenge
How do you publicly launch a company taking a completely new approach to drug discovery and development based on a new scientific approach?
Approach
We partnered with Kojin to support their Series A announcement and company launch. Our goals included:
-
- Develop focused communications program for the funding announcement
- Increase brand awareness and excitement with target audiences
- Develop a strong foundation for ongoing communications and hiring
We first spent time understanding the science as well as the company’s positioning, then worked together to refine Kojin’s messaging for the website and external audiences before developing the launch press release.
Impact
We reached out to business, trade, and VC outlets to secure seven interviews with key members of the founding Kojin team and board members.
The media coverage of the announcement engaged more than 89 million online readers and garnered 159,000 unique views from a mix of business and trade industry audiences. We secured key overage with high priority trade publications including Endpoints News and FierceBiotech as well as Boston Business Journal and funding-focused newsletters.
We also launched the company’s social media presence on LinkedIn and Twitter with a series of posts highlighting the news and subsequent coverage, as well as spotlights of the founding and executive team members.
Series A
funding announced
89+MM
